Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 5—May 2008

Scale-up of Multidrug-Resistant Tuberculosis Laboratory Services, Peru

Sonya S. Shin*Comments to Author , Martin Yagui†, Luis Ascencios†, Gloria Yale‡, Carmen Suarez‡, Neyda Quispe†, Cesar Bonilla‡, Joaquin Blaya§, Allison Taylor¶, Carmen Contreras#, and Peter Cegielski¶
Author affiliations: *Brigham and Women’s Hospital, Boston, Massachusetts, USA; †Instituto Nacional de Salud, Lima, Peru; ‡Programa de Control de Tuberculosis, Lima, Peru; §Partners in Health, Boston, Massachusetts, USA; ¶Centers for Disease Control and Prevention, Atlanta, Georgia, USA; #Socios en Salud, Lima, Peru;

Main Article

Table 1

HIV and tuberculosis (TB), Peru, 2005*

Characteristic Value
Total population 28,300,000
Population in Lima 7,300,000
Average life expectancy, y 69
Infant mortality rate 31/100,000 live births
GDP per capita $2,500
Population living in poverty 54%
National HIV prevalence 0.6%
Estimated no. HIV positive 60,000–80,000
No. receiving HIV therapy 9,157
TB incidence 108/100,000
MDR TB in new patients 3%
MDR TB in previously treated patients 12.3%
TB in HIV patients ≈30%
HIV in TB patients ≈3%
MDR TB in co-infected patients 30%–47%
Mortality rate among co-infected patients† <38%
Mortality rate among MDR TB–HIV patients <57%

*GDP, gross domestic product; MDR TB, multidrug-resistant TB.
†Co-infected with HIV and TB but not necessarily MDR-TB.

Main Article

Page created: July 08, 2010
Page updated: July 08, 2010
Page reviewed: July 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.